Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Melinta Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult (≥18 years of age) men or women with cSSSI
Diagnosis of one of the following 3 types of cSSSI: wound infection that has developed within 30 days of surgery, trauma, or a bite injury; abscess that has developed in the 7 days before enrollment; or cellulitis that has developed in the 7 days before enrollment
Sexually active men and women of childbearing potential must agree to use an acceptable form of contraception, as determined by the investigator, during participation in the study and for 30 days after the final dose of study drug
The patient must be willing to comply with protocol requirements
You may not be if
Medical history of hypersensitivity or allergic reaction to quinolones, tetracycline or tetracycline derivatives
Chronic or underlying skin condition at the site of infection
Infection involving prosthetic materials or foreign bodies (unless prosthetic material will be removed within 24 hours), infection associated with a human bite, osteomyelitis, decubitus ulcer, diabetic foot ulcer, septic arthritis, mediastinitis, necrotizing fasciitis, myositis, tendinitis, endocarditis, toxic shock syndrome, gangrene or gas gangrene, burns covering ≥10% of body surface area, severely impaired arterial blood supply, current evidence of deep vein thrombosis or superficial thrombophlebitis
An infection that would normally have a high cure rate after surgical incision alone
Any infection expected to require other antimicrobial agents in addition to study drug
Receipt of \>24 hours of systemic antibiotic therapy in the 7 days before enrollment
A severely compromised immune system
History of Child-Pugh Class B or C liver disease or severe renal impairment (creatinine clearance of \<30 mL/minute)
